↓ Skip to main content

Microrna expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms

Overview of attention for article published in Journal of Hematology & Oncology, December 2014
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
33 Dimensions

Readers on

mendeley
51 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Microrna expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms
Published in
Journal of Hematology & Oncology, December 2014
DOI 10.1186/s13045-014-0096-y
Pubmed ID
Authors

Maria Braoudaki, George I Lambrou, Krinio Giannikou, Vasilis Milionis, Kalliopi Stefanaki, Diane K Birks, Neophytos Prodromou, Aggeliki Kolialexi, Antonis Kattamis, Chara A Spiliopoulou, Fotini Tzortzatou-Stathopoulou, Emmanouel Kanavakis

Abstract

BackgroundAlthough, substantial experimental evidence related to diagnosis and treatment of pediatric central nervous system (CNS) neoplasms have been demonstrated, the understanding of the etiology and pathogenesis of the disease remains scarce. Recent microRNA (miRNA)-based research reveals the involvement of miRNAs in various aspects of CNS development and proposes that they might compose key molecules underlying oncogenesis. The current study evaluated miRNA differential expression detected between pediatric embryonal brain tumors and normal controls to characterize candidate biomarkers related to diagnosis, prognosis and therapy.MethodsOverall, 19 embryonal brain tumors; 15 Medulloblastomas (MBs) and 4 Atypical Teratoid/Rabdoid Tumors (AT/RTs) were studied. As controls, 13 samples were used; The First-Choice Human Brain Reference RNA and 12 samples from deceased children who underwent autopsy and were not present with any brain malignancy. RNA extraction was carried out using the Trizol method, whilst miRNA extraction was performed with the mirVANA miRNA isolation kit. The experimental approach included miRNA microarrays covering 1211 miRNAs. Quantitative Real-Time Polymerase Chain Reaction was performed to validate the expression profiles of miR-34a and miR-601 in all 32 samples initially screened with miRNA microarrays and in an additional independent cohort of 30 patients (21MBs and 9 AT/RTs). Moreover, meta-analyses was performed in total 27 embryonal tumor samples; 19 MBs, 8 ATRTs and 121 control samples. Twelve germinomas were also used as an independent validation cohort. All deregulated miRNAs were correlated to patients¿ clinical characteristics and pathological measures.ResultsIn several cases, there was a positive correlation between individual miRNA expression levels and laboratory or clinical characteristics. Based on that, miR-601 could serve as a putative tumor suppressor gene, whilst miR-34a as an oncogene. In general, miR-34a demonstrated oncogenic roles in all pediatric embryonal CNS neoplasms studied.ConclusionsDeeper understanding of the aberrant miRNA expression in pediatric embryonal brain tumors might aid in the development of tumor-specific miRNA signatures, which could potentially afford promising biomarkers related to diagnosis, prognosis and patient targeted therapy.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 51 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 18%
Student > Bachelor 9 18%
Student > Master 8 16%
Researcher 7 14%
Other 3 6%
Other 8 16%
Unknown 7 14%
Readers by discipline Count As %
Medicine and Dentistry 19 37%
Agricultural and Biological Sciences 9 18%
Biochemistry, Genetics and Molecular Biology 8 16%
Nursing and Health Professions 1 2%
Pharmacology, Toxicology and Pharmaceutical Science 1 2%
Other 4 8%
Unknown 9 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 January 2015.
All research outputs
#3,799,589
of 4,692,005 outputs
Outputs from Journal of Hematology & Oncology
#146
of 198 outputs
Outputs of similar age
#122,647
of 156,155 outputs
Outputs of similar age from Journal of Hematology & Oncology
#13
of 18 outputs
Altmetric has tracked 4,692,005 research outputs across all sources so far. This one is in the 3rd percentile – i.e., 3% of other outputs scored the same or lower than it.
So far Altmetric has tracked 198 research outputs from this source. They receive a mean Attention Score of 1.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 156,155 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.